EC and Pembrolizumb combination therapy with Pegfilgrastim as primary prevention

EC and Pembrolizumb combination therapy with Pegfilgrastim as primary prevention - ECOLOGY

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053351

Enrollment

Registered

2024-01-16

Start date

2023-11-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

triple negative breast cancer being treated by preoperative chemotherapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All the patients those who receive KN522 regimen for the treatment of stage II - III TNBC

Exclusion criteria

Exclusion criteria: Those who not gave written informed consent

Design outcomes

Primary

Measure	Time frame
prevalence of fevrile events, FN (true-FN, surrogate-FN), antibiotics usage, number of unplanned visits, irAE (including ILD), arthralgia, usage of pain medication, PPI usage, all adverse events Grade 2-4 (CTCAE ver.5), RDI, pCR, and laboratory data	—

Countries

Japan

Contacts

Public ContactMitsunori Morita

Hyogo Cancer Center Division of Medical Oncology

m-morita@hyogo-cc.jp+81-78-929-1151

Outcome results